Opus Capital Group’s Anavex Life Sciences AVXL Stock Holding History

Opus Capital Group’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98K	Hold	37,700	–	–	0.01%	143
2026 Q1	$116K	Hold	37,700	–	–	0.01%	133
2025 Q4	$134K	Buy	37,700 +3,000	+9%	+$18.4K	0.01%	130
2025 Q3	$309K	Hold	34,700	–	–	0.03%	98
2025 Q2	$320K	Hold	34,700	–	–	0.04%	92
2025 Q1	$298K	Hold	34,700	–	–	0.04%	95
2024 Q4	$373K	Buy	34,700 +2,000	+6%	+$15.4K	0.05%	84
2024 Q3	$186K	Hold	32,700	–	–	0.02%	116
2024 Q2	$138K	Buy	32,700 +2,200	+7%	+$8.9K	0.02%	115
2024 Q1	$155K	Hold	30,500	–	–	0.02%	119
2023 Q4	$284K	Hold	30,500	–	–	0.05%	100
2023 Q3	$200K	Buy	30,500 +4,000	+15%	+$31.8K	0.04%	110
2023 Q2	$215K	Hold	26,500	–	–	0.04%	115
2023 Q1	$227K	Hold	26,500	–	–	0.04%	110
2022 Q4	$245K	Buy	26,500 +10,000	+61%	+$107K	0.05%	103
2022 Q3	$170K	Hold	16,500	–	–	0.04%	105
2022 Q2	$165K	Hold	16,500	–	–	0.03%	109
2022 Q1	$203K	Hold	16,500	–	–	0.04%	106
2021 Q4	$286K	Hold	16,500	–	–	0.06%	88
2021 Q3	$296K	Buy	16,500 +6,000	+57%	+$119K	0.07%	83
2021 Q2	$240K	Buy	10,500 +500	+5%	+$7.41K	0.05%	102
2021 Q1	$150K	Hold	10,000	–	–	0.04%	124
2020 Q4	$54K	Hold	10,000	–	–	0.01%	127
2020 Q3	$46K	Buy	+10,000	New	+$43K	0.01%	116

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Opus Capital Group's AVXL Position: Q2 2026 in Review

Opus Capital Group held its Anavex Life Sciences (AVXL) position steady in Q2 2026 at 37,700 shares worth $98K. The position accounts for 0.01% of the portfolio, ranked #143.

Opus Capital Group first reported a position in AVXL in Q3 2020 and has held it in 24 quarters since. The position peaked at $373K in Q4 2024. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Opus Capital Group held 37,700 shares of Anavex Life Sciences worth $98K as of Q2 2026.
Opus Capital Group left its Anavex Life Sciences share count unchanged in Q2 2026.
Anavex Life Sciences made up 0.01% of Opus Capital Group's portfolio in Q2 2026, its #143 holding.
Opus Capital Group first reported a position in Anavex Life Sciences in Q3 2020 and has held it in 24 quarters since.
Opus Capital Group's Anavex Life Sciences position peaked at $373K in Q4 2024.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Opus Capital Group's 13F filing for Q2 2026, filed 31 Jul 2026.